<DOC>
	<DOCNO>NCT03072030</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , epidemiological efficacy safety medicinal product GamEvac-Combi - Combined Vector-Based Vaccine Ebola Virus Disease , 0.5 ml+0.5 ml/dose</brief_summary>
	<brief_title>International Multicenter Study Immunogenicity Medicinal Product GamEvac-Combi</brief_title>
	<detailed_description>This clinical trial design double blind randomize placebo-controlled study evaluate immunogenicity medicinal product GamEvac-Combi - Combined Vector-Based Vaccine Ebola Virus Disease , 0.5 ml+0.5 ml/dose . The study include three period : screening , administration investigate product follow-up . Vaccine administer group volunteer ( group include 40 volunteer time ; new group volunteer hospitalize earlier vaccinated volunteer discharge hospital . In total , 8 visit hold , include screen visit ; two visit take place inpatient stage six - outpatient observation . Study design facility volunteer , except biomaterial collect immunogenicity evaluation volunteer include study Russian Federation deliver directly test laboratory ; biomaterial volunteer include study Republic Guinea undergo primary specimen processing , frozen store assigned temperature condition research center , biomaterial accumulate , transport fridge study site . In addition , laboratory test concomitant infectious disease , yellow fever , Denge fever , Ebola Marburg virus disease carry epidemiological indication ( i.e . endemic region disease case report ) .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female within age range 18 60 year ; write informed consent ; absence acute infectious diseases/relapses chronic disease time vaccine administration 7 day prior vaccination ; absence severe allergic diseases medical history ( anaphylactic shock , Quincke 's edema , polymorphic exudative eczema , serum disease ) serious postvaccination complication patient 's history follow early administration immunobiological product negative blood urine test pregnancy ( childbearing age female ) 24 hour prior administration first dose investigated product ; absence concomitant illness , especially dangerous endemic particular region , prove laboratory and/or clinical method ( malaria , yellow fever , Denge fever , Ebola Marburg virus disease , poliomyelitis ) . negative result HIV , hepatitis B C syphilis test . adequate contraception female male reproductive age . negative result urine test narcotic drug residue ; negative result breath alcohol test ( expire air sample ) absence haematological malignancy absence malignant neoplasm volunteer involvement another study last 90 day ; immunization vaccine last 30 day ; symptom acute respiratory disease within last 7 day ; administration immunoglobulins blood product ; take immunosuppressive medication and/or immunomodulating agent last 3 month ; pregnancy breast feeding ; exacerbation allergic disease , previous history anaphylactic reaction angioneurotic edema ; previous history hypersensitivity allergic reaction administration vaccine ; allergic reaction vaccine component ; presence concomitant illness might affect evaluation study result : active tuberculosis form , chronic liver kidney disease , serious thyroid dysfunction endocrine disorder ( diabetes mellitus ) , severe hematopoietic disease , epilepsy CNS disorder , myocardial infarction medical history , myocarditis , endocarditis , pericarditis , ischemic heat disease illness , opinion investigator , make patient ineligible study enrollment may affect course study . blood donation ( 450 ml blood plasma ) less 2 month prior study commencement date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ebola Virus Disease</keyword>
	<keyword>Hemorrhagic Fever , Ebola</keyword>
	<keyword>Vaccines</keyword>
	<keyword>GP protein , Ebola virus</keyword>
	<keyword>Ebola Virus Vaccines</keyword>
</DOC>